Abstract: Objective To analyze the cost-effectiveness of irbesartan and amlodipine besylate in the treatment of essential hypertension in the elderly. Methods A total of 70 elderly patients with essential hypertension admitted to our hospital between September 2023 and July 2024 were included in this study.The patients were divided into two groups by the random number table method, with 35 people in each group, who were given oral treatment of amlodipine besylate and irbesartan respectively.The treatment effect, blood pressure changes before and after treatment, treatment cost and the occurrence of adverse effects were compared between the two groups. Results Amlodipine benzlate group was compared with irbesartan group (P>0.05). After 8 weeks of treatment, systolic, diastolic and mean arterial pressure in both groups were lower than before treatment, and amlodipine benzene late group was lower than irbesartan group (P<0.05). The direct cost of amlodipine group and average daily cost were lower than RMB (P<0.05). The C/E in the amlodipine benzlate group was better than that in the irbesartan group. The overall incidence of adverse effects in the amlodipine phenlate group and irbesartan group(P>0.05). Conclusion Amlodipine benzene late has similar therapeutic effect to irbesartan in treating essential hypertension in the elderly, but better performance in reducing blood pressure, reducing treatment cost and improving cost-effectiveness ratio.

Key words: amlodipine phenylate, irbesartan, essential hypertension in the elderly, cost-effectiveness